197 related articles for article (PubMed ID: 22461287)
1. Efficacy of ibandronate: a long term confirmation.
Di Munno O; Delle Sedie A
Clin Cases Miner Bone Metab; 2010 Jan; 7(1):23-6. PubMed ID: 22461287
[TBL] [Abstract][Full Text] [Related]
2. Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies.
Miller PD; Recker RR; Harris S; Silverman S; Felsenberg D; Reginster J; Day BM; Barr C; Masanauskaite D
Osteoporos Int; 2014 Jan; 25(1):349-57. PubMed ID: 24136103
[TBL] [Abstract][Full Text] [Related]
3. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.
Bianchi G; Czerwinski E; Kenwright A; Burdeska A; Recker RR; Felsenberg D
Osteoporos Int; 2012 Jun; 23(6):1769-78. PubMed ID: 21975558
[TBL] [Abstract][Full Text] [Related]
4. Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review.
Adami S; Idolazzi L; Rossini M
Ther Adv Musculoskelet Dis; 2011 Apr; 3(2):67-79. PubMed ID: 22870467
[TBL] [Abstract][Full Text] [Related]
5. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
Miller PD; McClung MR; Macovei L; Stakkestad JA; Luckey M; Bonvoisin B; Reginster JY; Recker RR; Hughes C; Lewiecki EM; Felsenberg D; Delmas PD; Kendler DL; Bolognese MA; Mairon N; Cooper C
J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
[TBL] [Abstract][Full Text] [Related]
6. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
Rossini M; Viapiana O; Gatti D; Adami S
Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
[TBL] [Abstract][Full Text] [Related]
7. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies.
Harris ST; Blumentals WA; Miller PD
Curr Med Res Opin; 2008 Jan; 24(1):237-45. PubMed ID: 18047776
[TBL] [Abstract][Full Text] [Related]
8. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
[TBL] [Abstract][Full Text] [Related]
9. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
Reginster JY; Felsenberg D; Cooper C; Stakkestad JA; Miller PD; Kendler DL; Adami S; McClung MR; Bolognese MA; Civitelli R; Dumont E; Bonvoisin B; Recker RR; Delmas PD
Osteoporos Int; 2006 Feb; 17(2):159-66. PubMed ID: 15959614
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.
Miller PD; Recker RR; Reginster JY; Riis BJ; Czerwinski E; Masanauskaite D; Kenwright A; Lorenc R; Stakkestad JA; Lakatos P
Osteoporos Int; 2012 Jun; 23(6):1747-56. PubMed ID: 21953471
[TBL] [Abstract][Full Text] [Related]
11. Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA.
Sambrook P; Cranney A; Adachi JD
Curr Med Res Opin; 2010 Mar; 26(3):599-604. PubMed ID: 20055751
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
Reginster JY; Adami S; Lakatos P; Greenwald M; Stepan JJ; Silverman SL; Christiansen C; Rowell L; Mairon N; Bonvoisin B; Drezner MK; Emkey R; Felsenberg D; Cooper C; Delmas PD; Miller PD
Ann Rheum Dis; 2006 May; 65(5):654-61. PubMed ID: 16339289
[TBL] [Abstract][Full Text] [Related]
13. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Epstein S; Jeglitsch M; McCloskey E
Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
[TBL] [Abstract][Full Text] [Related]
14. Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy.
Amling M; Kurth A
Womens Health (Lond); 2009 Sep; 5(5):467-73. PubMed ID: 19702445
[TBL] [Abstract][Full Text] [Related]
15. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
16. Once-monthly dosing: an effective step forward.
Reid DM
Bone; 2006 Apr; 38(4 Suppl 1):S18-22. PubMed ID: 16533625
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis.
Inderjeeth CA; Glendenning P; Ratnagobal S; Inderjeeth DC; Ondhia C
Int J Womens Health; 2015; 7():7-17. PubMed ID: 25565901
[TBL] [Abstract][Full Text] [Related]
18. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
Reginster JY
Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
Lee DR; Lee J
Osteoporos Int; 2019 Mar; 30(3):659-666. PubMed ID: 30535785
[TBL] [Abstract][Full Text] [Related]
20. Osteoporosis treatment: why ibandronic acid?
Rossini M; Orsolini G; Adami S; Kunnathully V; Gatti D
Expert Opin Pharmacother; 2013 Jul; 14(10):1371-81. PubMed ID: 23650954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
